Risperidone
- Risperidon INN
- risperidon
- Former
- Depotindsprøjtning (langtidsvirkende)
- Område
- Skizofreni
- Alternativer
- Ja
What is this? Risperidone is a medicine used to treat schizophrenia. It comes as a shot that lasts for weeks.
What's happening? There is not enough of this shot right now in the EU. Other forms of risperidone are still available.
Does this affect me? If you take this shot for schizophrenia, you may be affected. Check with your doctor.
What should I do? Talk to your pharmacist or doctor before making any changes to your medicine.
🤖 Denne letforståelige oversigt er automatisk genereret ud fra den officielle meddelelse fra myndigheden ved hjælp af AI. Den er udelukkende til generel information — ikke medicinsk rådgivning. Vedrørende beslutninger om din sundhed, skal du altid konsultere en farmaceut eller læge og læse den officielle kilde, der er linket nedenfor.
📋 Fra den officielle meddelelse fra myndigheden
Opdateret for 1 uge siden- Først udgivet
- 19/11/2025
- Berørte lægemidler
- Risperidone
- Forventet opløsning
- Risperdal Consta - by the end of 2025 Risperidone Teva and Sperizak - to continue until the end of 2026 or beginning of 2027
- Lagerstatus
- Ongoing
- Terapirigt område (MESH)
- Schizophrenia
- Tilgængelighed af alternativer
- Yes
- Berørte lægemiddelformer
- Prolonged-release suspension for injection
- Internationalt ikke-ejendomsretligt navn (INN) eller fællesnavn
- risperidone
Sideindhold
Mangel på lager
There are shortages of several risperidone prolonged-release suspension for injection products (Risperidone Teva, Risperdal Consta and Sperizak) in several EU Member States.
These medicines are used to treat schizophrenia in adults and are given as an injection into the muscle.
The companies producing Risperidone Teva, Risperdal Consta and Sperizak are experiencing manufacturing problems, which have led to shortages of these medicines.
The shortage of Risperdal Consta is expected to be resolved by the end of 2025. Those of Risperidone Teva and Sperizak are expected to continue until the end of 2026 or beginning of 2027.
The shortages are not related to a quality defect of the product or a safety issue.
The shortages affect several Member States where the products are marketed.
As the shortage situation is changing quickly, for up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the impacted marketing authorisation holders and alternative marketing authorisation holders to reduce the impact of the supply shortage and ensure a fair distribution of stock among the Member States.
The SPOC Working Party Supports EMA’s MSSG and monitors and reports events that could affect the supply of medicines in the EU.
- There is a shortage of Risperidone Teva, Risperdal Consta and Sperizak prolonged-release suspension for injection in several EU Member States.
- The shortage of Risperdal Consta is expected to be resolved by the end of 2025. Those of Risperidone Teva and Sperizak are expected to continue until the end of 2026 or beginning of 2027.
- Before initiating treatment with these medicines, you should check with your national competent authority in case they have issued national recommendations.
- There may be alternative prolonged-release risperidone medicines authorised in your country which can be used instead. If there is no alternative prolonged-release risperidone medicine, you should consider switching patients to an alternative treatment.
- For additional information, consult your country’s shortage register or contact your national competent authority.
- You may also contact relevant healthcare professional organisations for further information. A list of European not-for-profit organisations EMA engages with can be found on the EMA website.
- There is a shortage of Risperidone Teva, Risperdal Consta and Sperizak prolonged-release suspension for injection in several EU Member States.
- The shortage of Risperdal Consta is expected to be resolved by the end of 2025. Those of Risperidone Teva and Sperizak are expected to continue until the end of 2026 or beginning of 2027.
- There may be alternative prolonged-release risperidone medicines authorised in your country which can be used instead. If there is no alternative prolonged-release risperidone medicine, your doctor will discuss treatment alternatives with you.
- Contact your pharmacy or doctor well before your current supply runs out.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Årsag til mangel
The companies producing Risperidone Teva, Risperdal Consta and Sperizak are experiencing manufacturing problems, which have led to shortages of these medicines.
The shortage of Risperdal Consta is expected to be resolved by the end of 2025. Those of Risperidone Teva and Sperizak are expected to continue until the end of 2026 or beginning of 2027.
The shortages are not related to a quality defect of the product or a safety issue.
Berørte medlemsstater
The shortages affect several Member States where the products are marketed.
As the shortage situation is changing quickly, for up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.
Overvågning af mangel
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the impacted marketing authorisation holders and alternative marketing authorisation holders to reduce the impact of the supply shortage and ensure a fair distribution of stock among the Member States.
The SPOC Working Party Supports EMA’s MSSG and monitors and reports events that could affect the supply of medicines in the EU.
Anbefalinger til sundhedspersonale
- There is a shortage of Risperidone Teva, Risperdal Consta and Sperizak prolonged-release suspension for injection in several EU Member States.
- The shortage of Risperdal Consta is expected to be resolved by the end of 2025. Those of Risperidone Teva and Sperizak are expected to continue until the end of 2026 or beginning of 2027.
- Before initiating treatment with these medicines, you should check with your national competent authority in case they have issued national recommendations.
- There may be alternative prolonged-release risperidone medicines authorised in your country which can be used instead. If there is no alternative prolonged-release risperidone medicine, you should consider switching patients to an alternative treatment.
- For additional information, consult your country’s shortage register or contact your national competent authority.
- You may also contact relevant healthcare professional organisations for further information. A list of European not-for-profit organisations EMA engages with can be found on the EMA website.
Anbefalinger til patienter og pårørende
- There is a shortage of Risperidone Teva, Risperdal Consta and Sperizak prolonged-release suspension for injection in several EU Member States.
- The shortage of Risperdal Consta is expected to be resolved by the end of 2025. Those of Risperidone Teva and Sperizak are expected to continue until the end of 2026 or beginning of 2027.
- There may be alternative prolonged-release risperidone medicines authorised in your country which can be used instead. If there is no alternative prolonged-release risperidone medicine, your doctor will discuss treatment alternatives with you.
- Contact your pharmacy or doctor well before your current supply runs out.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Nøgleoplysninger
- Medicines affected
- Risperidone
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- risperidone
- Therapeutic area (MESH)
- Schizophrenia
- Pharmaceutical forms affected
- Prolonged-release suspension for injection
- Availability of alternatives
- Yes
Nøgledatoer
- Expected resolution
- Risperdal Consta - by the end of 2025
Risperidone Teva and Sperizak - to continue until the end of 2026 or beginning of 2027 - First published
Relateret medicinsk information
🔬 Medicinske/tekniske detaljer Til fagfolk
INN: risperidone · Forms: Prolonged-release suspension for injection · Area: Schizophrenia · Alternatives: Yes
Alle oplysninger på denne side stammer fra den officielle meddelelse fra myndighederne. Vi oversætter og opsummerer den; vi tilføjer eller redigerer ikke fakta.
